

Bactericidal Efficacy of *Allium sativum* (garlic) Against Multidrug Resistant *Vibrio cholerae* O1 Epidemic Strains

Pramod Kumar^{1, #}, Jayprakash Yadav[#], Meenu Jain[#], Preeti Yadav[#],
A.K. Goel[#], and Pramod Kumar Yadava^{1, *}

¹School of Life Sciences, Jawaharlal Nehru University, New Delhi - 110 067, India

[#]Defence Research and Development Establishment, Gwalior – 474 002, India

*E-mail: pkyadava1953@gmail.com

ABSTRACT

In recent years, emerging trend of antibiotic resistance in *Vibrio cholerae* associated with cholera epidemics is a matter of serious concern for the management of the disease. Indiscriminate use of antibiotics generally results in selection of antibiotic resistant strains. Introduction of newer antibiotics is a challenging task for the researchers as bacteria soon attain resistance. Therefore, identifying natural compounds of medicinal importance for control of cholera would be the best alternative. Garlic (*Allium sativum*) was recognised for many centuries in early Chinese, Egyptian and Indian civilisations as an herbal or traditional medicine. In present study, garlic was selected for screening of antimicrobial efficacy against *V. cholerae*. A total of 55 *V. cholerae* strains isolated from various outbreaks/epidemics were subjected to antimicrobial testing as per CLSI, USA 2010 guidelines. Antimicrobial screening of garlic extract was performed against all the multidrug resistant strains of *V. cholerae*. The garlic extracts showed antibacterial activity against all the *V. cholerae* strains tested, irrespective of their origin, multidrug resistance and virulence. Antibacterial efficacy of garlic on *V. cholerae* was also evident from *in vivo* study on sealed adult mice model. Thus, the Garlic extract harnesses the potential to control infection of multidrug resistant *V. cholerae*, especially in outbreak like situations in remote and under developed areas where drug supply itself is a challenge.

Keywords: Antimicrobial activity, garlic, multidrug resistance and *V. cholerae*

1. INTRODUCTION

Cholera is a potentially epidemic and life-threatening diarrheal disease that continues to strike many developing countries, where access to safe drinking water and adequate sanitation cannot be assured¹. Almost every developing country is now facing either a cholera outbreak or the threat of epidemic, which along with serious public health problems severely affects the economy too. The World Health Organisation (WHO) estimates every year there are 1.4 to 4.3 million cases of cholera associated with 28,000 to 1,42,000 deaths worldwide². The disease is endemic in many states of India as per the new definition of endemic cholera devised by WHO Strategic Advisory Group of Experts (SAGE) in 2009³.

The introduction of oral rehydration suspension (ORS) for cholera treatment by the WHO greatly diminished the disease mortality. Use of effective antibiotics shortens the duration of diarrhea, reduction in the disease severity thereby curbing secondary transmission. While considering cholera management, the emergence of wide-spread antibiotic resistant *V. cholerae* strains presents the greatest challenges for the developing countries⁴. Occurrence of multiple antibiotic resistant *V. cholerae* has been on the rise among outbreak

strains^{5,6}. Switch in the resistance pattern from one drug to another has also been observed during the management of the outbreaks⁷. Now, most of the *V. cholerae* isolates are becoming resistant to low cost first-line drugs like tetracycline and trimethoprim-sulfamethoxazole⁸. Multidrug resistance in *V. cholerae* is a result of acquisition of genetic elements located within the chromosomal DNA, such as integrons and SXT constin, as vehicles of the transport of genetic determinants responsible for resistance⁹⁻¹¹. Recently, most of the large cholera outbreaks were associated with *V. cholerae* having multidrug resistance mediated by SXT and integron elements¹²⁻¹⁴. Thus, antimicrobial resistance can increase the outbreak size, duration and case fatality rates. Therefore, alternative treatment approaches like use of antibacterial herbs need to be explored for combating the disease.

The importance of garlic (*Allium sativum*) was recognised for many centuries in early Chinese, Egyptian and Indian civilisations as a herbal or traditional medicine. It is a member of the Liliaceae family and probably one of the earliest known medicinal plants used worldwide to reduce various risk factors¹⁵. It has sulfur containing compounds like allicin which is considered responsible for its antibacterial properties. Allicin is biosynthesised from alliin by the action of enzyme alliinase. It harbors a thiosulfinate functional group, R-S(O)-

S-R which is associated with main antimicrobial effect due to its chemical reaction with thiol groups of various microbial enzymes essential for metabolism¹⁶.

Antibacterial properties of garlic extract or allicin have been reported against a number of pathogenic bacteria viz. *E. coli*¹⁷, *V. cholerae*^{18, 19}, *Pseudomonas aeruginosa*²⁰, *Salmonella typhimurium*¹⁸, *Streptococcus pneumoniae*²¹, *Staphylococcus aureus*²² and Methicillin resistant *S. aureus* (MRSA)^{23,24}. Present study was aimed to check the efficacy of garlic extract against multidrug resistant *V. cholerae* having epidemic potential isolated from different outbreaks in India.

2. MATERIAL AND METHODS

2.1 *V. cholerae* Strains

Total 55 clinical isolates collected from different parts of India (Table 1) were used in this study.

2.2 Antimicrobial Susceptibility Testing

Clinical strains of *V. cholerae* were tested for antimicrobial drug susceptibility by disc diffusion method on Mueller–Hinton agar (MHA) according to the standard procedure²⁵. The antibiotic discs (Oxoid limited, UK and Himedia, India) used were: ampicillin (Amp), chloramphenicol (chl), ciprofloxacin (Cip), doxycycline (Dox), erythromycin (Ery), gentamicin (Gen), nalidixic acid (NA), streptomycin (Str), sulfamethoxazole (Sul), tetracycline (TE), trimethoprim (Tri) and the vibrio static agent O/129.

2.3 Preparation of Garlic Extract

Garlic (*Allium Sativum*) extraction was done according to the earlier described methods²¹. The extract was stored in sterilised bottles at -20 °C. One ml of aqueous extract contained material from 500 mg of garlic. The required dilutions of the

garlic extract were prepared in autoclaved double distilled water on the day of experiment. The extract was centrifuged at 5000 g for 15 min; the supernatant was collected and filtered through 0.45 µm membrane filters.

2.4 Determination of Minimum Inhibitory Concentration

MICs of garlic against the randomly selected clinical and environmental *V. cholerae* strains was determined by agar well diffusion and broth micro-dilution using two-fold serial dilutions, as per standard procedure²⁵.

2.5 Time Kill Assay

Randomly selected *V. cholerae* clinical and environmental strains carrying SXT and integron were subjected to time kill assay²³. The strains were overnight grown in Mueller Hinton broth (MHB). Bacterial inocula equal to 5×10^5 CFU/ml were added to a double strength of MHB (5 ml) containing garlic extract (equivalent to 1 x MIC or 10 x MIC of that particular bacterial strain) and the volume was adjusted to 10 ml by adding sterile double distilled water. The control group which did not receive garlic was run in parallel. A 100 µl of culture broth was harvested at 0 h, 2 h, 4 h, 6 h, and 8 h followed by 10-fold serial dilutions of the inoculums in normal saline and plating on MHA plates. After incubation at 37 °C for 24 h, the colonies were counted. Growth was observed further for 48 h.

2.6 Analysis of Antimicrobial Activity on Thin Layer Chromatographic (TLC) Plate

Garlic extract was run on TLC plates using solvent containing ethyl acetate, methanol and water (81:11:8). *V. cholerae* strains grown to exponential phase were harvested, the inoculum was adjusted to 0.5 McFarland standard and

Table 1. Susceptibility of Multidrug resistant *V. cholerae* clinical isolates (collected from different outbreaks in India) towards aqueous extract of garlic

| Year of isolation | Location | No. of strains | Efficacy of garlic | Antibiotic phenotype | Antibiotic genotype | | Reference |
|-------------------|----------------------|----------------|--------------------|------------------------------|---------------------|----------|-----------|
| | | | | | SXT | Integron | |
| 2004 | Chennai, India | 05 | + | Na, Str, Sul, Tri, O129 | + | + | 11 |
| 2007 | Rayagada, Orissa | 05 | + | Na, Str, Sul, Tri, O129 | + | + | 6, 8 |
| 2007 | Kalahandi, Orissa | 05 | + | Na, Str, Sul, Tri, O129 | + | + | 6, 8 |
| 2007 | Koraput, Orissa | 05 | + | Na, Str, Sul, Tri, O129 | + | + | 6, 8 |
| 2009 | Datia, Morena | 05 | + | Na, Str, Sul, Tri, O129 | + | + | |
| 2009 | Hydrabad | 05 | + | Na, Str, Sul, Tri, O129 | + | + | 12 |
| 2010 | Solapur, Maharashtra | 05 | + | Na, Str, Sul, Tri, O129 | + | + | |
| 2010 | Orissa | 05 | + | Na, Str, Sul, Tet, Tri, O129 | + | + | 4 |
| 2011 | Solapur | 05 | + | Na, Str, Sul, Tet, Tri, O129 | + | + | |
| 2011 | Gwalior | 05 | + | Na, Str, Sul, Tri, O129 | + | + | |
| 2012 | Yavatmal | 05 | + | Na, Str, Sul, Tri, O129 | + | + | 5, 10 |
| | Total | 55 | | | | | |

further diluted in molten Mueller Hinton Agar (45 °C - 50 °C) at a final concentration of 5×10^5 CFU/ml. The suspension was immediately overlaid on prepared TLC plate and incubated at 37 °C for 24 h.

2.7 LC-MS Analysis of Garlic Extract

For liquid chromatography, the following solvent composition was made for sample introduction: solvent A (0.01M ammonium formate in water) and solvent B (0.01M ammonium formate in methanol). Chromatographic separations were performed using 0 per cent B (0 – 3 min), 0 – 100 per cent B (3 – 30 min) and 100 per cent B (30 – 40 min) at a flow rate of 200 μLmin^{-1} . Column temperature was kept at 25 °C. Samples were injected through a Rheodyne injector (Model 7010) fitted with 2 μL loop.

Mass spectral analyses were performed on Micromass Q-ToF high resolution mass spectrometer equipped with electrospray ionisation (ESI) on Masslynx 4.0 data acquisition system. ESI was used in +ve ionisation mode. Capillary and tube lens voltages were optimised to give the maximum response. Helium was continually flowing into the collision cell at a pressure of 0.1 Pa. (10–3 Torr) during the electrospray ionisation tandem-mass spectrometry (ESI-MS) operation. The ESI-MS data were acquired over the mass range of m/z 100 amu – 400 amu. The mass spectra were obtained at collision energy of 35 per cent.

2.8 *In vivo* Testing of Garlic Extract in Cholera Model

Balb/c mice (weight 20 g - 24 g) were used in this study. Sealed adult mice (SAM) model was prepared according to the previously described methods with some modifications²⁶. In brief, mice were starved overnight, anorectally canal was sealed with nail polish, given 500 μl of 2 per cent NaHCO_3 prior to administration of either bacterial inocula (10^9 CFU/ml) or bacteria followed by herbal extract ($n = 4$ mice/group) after 1 h and sacrificed at 6 h or 24 h. The intestine weight to carcass weight ratios was determined. In this experiment, we used Haitian type of CT producing strains as the strains were associated with a higher mortality in the epidemics. The control group of SAM ($n = 4$) received only PBS. They were kept in wired-mesh polyacrylic cages and fed with the standard rodent pellet diet and given water *ad libitum*. The animals were housed under standard laboratory environmental conditions for acclimatisation prior to making cholera model and performing the experiments.

3 RESULTS

3.1 Antimicrobial Susceptibility Pattern

The clinical *V. cholerae* isolates exhibited varied phenotypic resistance towards the antibiotics ampicillin, chloramphenicol, aminoglycosides, macrolides, quinolones, fluoroquinolones, sulfamethoxazole, trimethoprim and tetracyclines. The antibiogram of clinical isolates has been presented in Table 1.

3.2 Antibacterial Activity of Garlic Against *V. cholerae* Strains

Garlic aqueous extract presented antibacterial activity against all the clinical isolates tested (Table 1). The garlic extract (500 mg/ml) exhibited the zone of inhibition in the range of 19 mm to 27 mm diameter against clinical isolates (Fig. 1). The MIC in broth dilution ranged from 4 mg/ml - 16 mg/ml of garlic extract for *V. cholerae* ATCC 14033 and randomly selected epidemic strains resistant to important drugs used for cholera treatment viz. tetracycline and ciprofloxacin.




Figure 1. Size of zones of inhibition with garlic aqueous extract (500 mg/mL) against multidrug resistant *V. cholerae*.

3.3 Time Kill Curve

Time kill curves showed that 1X MIC of garlic killed the strains within 6 h, whereas, 10X MIC of garlic greatly reduced the viable count and killed the strains within 4 h (Fig. 2).




Figure 2. *In vitro* time dependent bactericidal effect of garlic extract on multidrug resistant *V. cholerae*. Minimum inhibitory concentration (MIC) of garlic extract was used as MIC-1X and MIC-10X (10 fold) in broth culture.

3.4 Antimicrobial Activity of Garlic Extract on TLC Plate

The zone of clearance was observed on TLC plate

indicating the *V. cholerae* growth inhibition due to presence of active antimicrobial compound at that particular position. A 0.54 R_f value was observed reflecting the zone of inhibition.

3.5 Allicin Peak Identified in LC-MS

Separation of the components of aqueous extracts of garlic was done on a C-18 column. In comparison to a reported retention time, the allicin peak has been tentatively identified (Fig. 3) which is the main component of garlic. On heating the aqueous extract of garlic for about 10 min at boiling water, the allicin peak was reduced significantly as a result of thermal instability of allicin. To confirm the identity of the isolated allicin, the extracts were then analysed by LC-MS.




Figure 3. LC-MS profile of *Allium sativum* (garlic) extract.

3.6 In-vivo Efficacy of Herbs in Cholera Model

A doze of 1×10^9 CFU of the epidemic *V. cholerae* strains (carrying Haitian CT) was able to induce cholera as significant fluid accumulation was observed in SAM (Fig. 4). The group of SAM administered with garlic extract following 1×10^9 CFU of the bacteria showed significant reduction in the fluid accumulation. The FA ratio of treated group was found very near to the control group which received only PBS.




Figure 4. In-vivo efficacy of garlic in cholera (SAM) model. A: Mice received buffer only, B: mice received *V. cholerae* and C: Mice received *V. cholerae* followed by administration of garlic extract.

4. DISCUSSION

Multiple antibiotic resistances among *V. cholerae* have emerged as a major problem worldwide. The occurrence of

antibiotic-resistant strains of *V. cholerae* is being reported with increasing frequency. In the process, the bacteria are continuously changing their genetic makeup for sustained infectivity^{8,13,14,27}. Acquisition of antibiotic resistance genes across genera and species is mediated through horizontal and lateral gene transfer of mobile genetic elements like SXT and integron^{10,28}.

Inappropriate and inadequate practices like misuse, abuse and over prescription of antibiotics are common in developing countries^{29,30}. In developing countries, the antimicrobial therapy is usually started even before the microbiological analysis⁵. Doxycycline and tetracycline are the preferred antibiotics given in severe cases for treatment but in recent year reemergence of

tetracycline resistant clones have been documented in India and other parts of the world, raising the question for their use³¹. Till date *V. cholerae* has acquired resistance to all commonly available antibiotics, therefore in outbreak like situation the prescription of effective antibiotic for combating the disease based on the trend of resistance cannot be assured without knowing antibiogram in laboratory conditions, a process that takes at least 2 - 3 days. In that, situation garlic extract can be made easily available for severely diseased persons. Medicinal plants are a rich source of antimicrobial agents and provide a safer and cost effective way of treating

bacterial infections. In Ayurvedic and Yunani medicine, herbs have been used to treat many infectious diseases for centuries including the treatment of dysentery and watery diarrhea. Garlic is commonly available and used as dietary supplement all over the world. It is also used to cure abdominal pain and severe diarrhea by Arabian herbalists³². The *in vitro* activity of garlic has been reported against diverse enteric pathogen and diarrheagenic bacteria like *E. coli* O157, *Enterobacter cloacae*, *Enterococcus faecalis*, *Citrobacter freundii*, *S. typhi*, *S. dysenteriae*, and *V. cholerae*^{17,18,20-22}.

The effect of garlic was bactericidal as there was no growth observed on BHI agar till 48 h following 8 h of treatment with garlic (8 mg/ml). The main antimicrobial effect of garlic is due to the presence of diallyl sulphides and allicin is the most abundant sulfoxide molecule in garlic extract responsible for therapeutic potential including bactericidal activity^{23,26}. The functional group of allicin react with thiol groups in the active site of various microbial enzymes, e.g. alcohol dehydrogenase, thioredoxin reductase, and RNA polymerase and affect essential microbial metabolism¹⁶. Allicin is produced upon tissue damage from the non-proteinogenic amino acid alliin (*S*-allylcysteine sulfoxide) in a reaction that is catalysed by the enzyme alliinase¹⁶. The activity of alliinase reduces on boiling. Therefore, fresh garlic extracts is prepared

for extraction of optimum active fractions. The European Scientific Cooperative on Phytotherapy recommended garlic to cure upper respiratory tract infections³³. The antibacterial activity of garlic extract against intestinal bacteria is reported superior than tetracycline³⁴. A human trial conducted in different hospitals in China revealed the efficacy of garlic preparation in controlling *Cryptosporidium parvum* diarrhea in AIDS patients with weakened immune system³⁵. Our study indicated that aqueous garlic juice can act as broad spectrum antibacterial agent in managing cholera outbreaks. Furthermore, it can be used as nutritional supplement in the affected areas for the prevention of cholera spread.

REFERENCES

- Bhattacharyya S.; Shant J.; Ganguly N.K.; Majumdar S. & Ghosh S. A potential epidemic factor from the bacteria, *Vibrio cholerae* WO7. *Curr. Microbiol.*, 2008, **56**(1), 98-103. doi: 10.1007/s00284-007-9048-x
- Ali M.; Lopez A.L.; You Y.A.; Kim Y.E.; Sah B.; Maskery B., *et al.* The global burden of cholera. *Bull. World Health Organ.*, 2012, **90**(3), 209-218A. doi:10.2471/BLT.11.093427
- Sarkar B.L.; Kanungo S. & Nair G.B. How endemic is cholera in India? *Indian J. Med. Res.*, 2012, **135**, 246-248.
- Singh R.B.; Hales S.; de Wet N.; Raj R.; Hearnden M. & Weinstein P. The influence of climate variation and change on diarrheal disease in the Pacific Islands. *Environ. Health Perspect.*, 2001, **109**(2), 155-159. doi: 10.2307/3434769
- Sharma D.; Reeta K.; Badyal D.K.; Garg S.K. & Bhargava V.K. Antimicrobial prescribing pattern in an Indian tertiary hospital. *Indian J. Physiol. Pharmacol.*, 1998, **42**(4), 533-537.
- Kumar P.; Jain M.; Goel A.K.; Kamboj D.V. & Kumar O. Tetracycline resistant *V. cholerae* O1 biotype El Tor serotype Ogawa with classical ctxB from a recent cholera outbreak in Orissa, Eastern India. *J. Infect. Public Health*, 2012, **5**(2), 217-219. doi:10.1016/j.jiph.2011.09.007
- Kumar P.; Mishra D.K.; Deshmukh D.G.; Jain M.; Zade A.M.; Ingole K.V., *et al.* Haitian variant ctxB producing *Vibrio cholerae* O1 with reduced susceptibility to ciprofloxacin is persistent in Yavatmal, Maharashtra, India, after causing a cholera outbreak. *Clin. Microbiol. Infect.*, 2014, **20**(5), O292-293. doi:10.1111/1469-0691.12393
- Kumar P.; Jain M.; Goel A.K.; Bhadauria S.; Sharma S.K.; Kamboj D.V., *et al.* A large cholera outbreak due to a new cholera toxin variant of the *Vibrio cholerae* O1 El Tor biotype in Orissa, Eastern India. *J. Med. Microbiol.*, 2009, **58**(Pt 2), 234-238. doi:10.1099/jmm.0.002089-0
- Hochhut B.; Lotfi Y.; Mazel D.; Faruque S.M.; Woodgate R. & Waldor M.K. Molecular analysis of antibiotic resistance gene clusters in *Vibrio cholerae* O139 and O1 SXT constins. *Antimicrob. Agents Chemother.*, 2001, **45**(11), 2991-3000. doi: 10.1128/AAC.45.11.2991-3000.2001
- Jain M.; Kumar P.; Goel A.K.; Kamboj D.V. & Singh L. Class I integrons and SXT elements conferring multidrug resistance in *Vibrio cholerae* O1 strains associated with a recent large cholera outbreak in Orissa, Eastern India. *Int. J. Antimicrob. Agents*, 2008, **32**(5), 459-460. doi: 10.1016/j.ijantimicag.2008.05.003
- Das M.; Jaiswal A.; Pal S.; Bhowmick T.S.; Ghosh A.; Goel A.K., *et al.* Dynamics of classical-El Tor switch of *Vibrio cholerae* strains isolated from 1961-2010. *Int. J. Antimicrob. Agents*, 2012, **40**(6), 570-571. doi: 10.1016/j.ijantimicag.2012.08.005
- Kumar P.; Mishra D.K.; Deshmukh D.G.; Jain M.; Zade A.M.; Ingole K.V., *et al.* *Vibrio cholerae* O1 Ogawa El Tor strains with the ctxB7 allele driving cholera outbreaks in south-western India in 2012. *Infect. Genet. Evol.*, 2014, **25**, 93-96. doi: 10.1016/j.meegid.2014.03.020
- Goel A.K. & Jiang S.C. Genetic determinants of virulence, antibiogram and altered biotype among the *Vibrio cholerae* O1 isolates from different cholera outbreaks in India. *Infect. Genet. Evol.*, 2010, **10**(6), 815-819. doi:10.1016/j.meegid.2009.06.022
- Goel A.K.; Jain M.; Kumar P.; Sarguna P.; Bai M.; Ghosh N., *et al.* Molecular characterisation reveals involvement of altered El Tor biotype *Vibrio cholerae* O1 strains in cholera outbreak at Hyderabad, India. *J. Microbiol.*, 2011, **49**(2), 280-284. doi:10.1007/s12275-011-0317-9
- Metwally M.A.A. Effects of garlic (*Allium sativum*) on some antioxidant activities in tilapia nilotica (*Oreochromis niloticus*). *World J. Fish Marine Sci.*, 2009, **1**(1), 56-64.
- Ankri S. & Mirelman D. Antimicrobial properties of allicin from garlic. *Microbes Infect.*, 1999, **1**(2), 125-129.
- Sasaki J.; Kita T.; Ishita K.; Uchisawa H. & Matsue H. Antibacterial activity of garlic powder against *Escherichia coli* O-157. *J. Nutr. Sci. Vitaminol. (Tokyo)*, 1999, **45**(6), 785-790.
- Bernbom N.; Ng Y.Y.; Paludan-Muller C. & Gram L. Survival and growth of *Salmonella* and *Vibrio* in som-fak, a Thai low-salt garlic containing fermented fish product. *Int. J. Food Microbiol.*, 2009, **134**(3), 223-229. doi:10.1016/j.ijfoodmicro.2009.06.012
- Rattanachaiakunsopon P. & Phumkhachorn P. Antimicrobial activity of elephant garlic oil against *Vibrio cholerae* in vitro and in a food model. *Biosci. Biotechnol. Biochem.*, 2009, **73**(7), 1623-1627. doi:10.1271/bbb.90128
- Saha S.K.; Saha S.; Hossain M.A. & Paul S.K. *In vitro* assessment of antibacterial effect of garlic (*Allium sativum*) extracts on *Pseudomonas aeruginosa*. *Mymensingh. Med. J.*, 2015, **24**(2), 222-232.
- Dikasso D.; Lemma H.; Urga K.; Debella A.; Addis G.; Tadele A., *et al.* Investigation on the antibacterial properties of garlic (*Allium sativum*) on pneumonia causing bacteria. *Ethiop. Med. J.*, 2002, **40**(3), 241-249.
- Palaksha M.N.; Ahmed M. & Das S. Antibacterial activity

- of garlic extract on streptomycin-resistant *Staphylococcus aureus* and *Escherichia coli* solely and in synergism with streptomycin. *J. Nat. Sci. Biol. Med.*, 2010, **1**(1), 12-15. doi:10.4103/0976-9668.71666
23. Cutler R.R.; Odent M.; Hajj-Ahmad H.; Maharjan S.; Bennett N.J.; Josling P.D., *et al.* In vitro activity of an aqueous allicin extract and a novel allicin topical gel formulation against Lancefield group B streptococci. *J. Antimicrob. Chemother.*, 2009, **63**(1), 151-154. doi:10.1093/jac/dkn457
 24. Cutler R.R. & Wilson P. Antibacterial activity of a new, stable, aqueous extract of allicin against methicillin-resistant *Staphylococcus aureus*. *Br. J. Biomed. Sci.*, 2004, **61**(2), 71-74.
 25. CLSI. Performance standards for antimicrobial susceptibility testing. *Twenty second informational Supplement: CLSI document M100-S22* Wayne PA, USA, 2012.
 26. Thakurta P.; Bhowmik P.; Mukherjee S.; Hajra T.K.; Patra A. & Bag P.K. Antibacterial, antisecretory and antihemorrhagic activity of *Azadirachta indica* used to treat cholera and diarrhea in India. *J. Ethnopharmacol.*, 2007, **111**(3), 607-612. doi:10.1016/j.jep.2007.01.022
 27. Bhuyan S.K.; Vairale M.G.; Arya N.; Yadav P.; Veer V.; Singh L., *et al.* Molecular epidemiology of *Vibrio cholerae* associated with flood in Brahmaputra River valley, Assam, India. *Infect. Genet. Evol.*, 2016, **40**, 352-356. doi:10.1016/j.meegid.2015.11.029
 28. Beaber J.W.; Hochhut B. & Waldor M.K. SOS response promotes horizontal dissemination of antibiotic resistance genes. *Nature*, 2004, **427**(6969), 72-74. doi: 10.1038/nature02241
 29. Lakshmi V. Need for national/regional guidelines and policies in India to combat antibiotic resistance. *Indian J. Med. Microbiol.*, 2008, **26**(2), 105-107.
 30. Kumari-Indra K.S.; Chandy S.J.; Jeyaseelan L.; Kumar R. & Suresh S. Antimicrobial prescription patterns for common acute infections in some rural and urban health facilities of India. *Indian J. Med. Res.*, 2008, **128**(2), 165-171.
 31. Jain M.; Kumar P. & Goel A.K. Emergence of tetracycline resistant *Vibrio cholerae* O1 biotype El Tor serotype Ogawa with classical ctxB gene from a cholera outbreak in Odisha, Eastern India. *J. Pathog.*, 2016, **2016**, 1695410. doi:10.1155/2016/1695410
 32. Musselman L.J. Handbook of arabian medicinal plants. Shahina A. Ghazanfar. *Econ. Bot.*, 1995, **49**(4), 422-422. doi:10.1007/bf02863093
 33. Schilcher H. *Phytotherapy in paediatrics : handbook for physicians and pharmacists*. Berlin: Medpharm Scientific Publishers, 1997.
 34. Shashikanth K.N.; Basappa S.C. & Sreenivasa Murthy V. A comparative study of raw garlic extract and tetracycline on caecal microflora and serum proteins of albino rats. *Folia Microbiol. (Praha)*, 1984, **29**(4), 348-352.
 35. Fareed G.; Scolaro M.; Jordan W.; Sanders N.; Chesson C.; Seattery M., *et al.* The use of a high-dose garlic preparation for the treatment of *Cryptosporidium parvum* diarrhea. *Proc. Intern. Conf. AIDS*, 1996, **11**, 288.

Conflict of Interest: None

ACKNOWLEDGEMENTS

Authors are thankful to Director Defence Research & Development Establishment, Gwalior, India for providing the facility for LC-MS analysis of samples. Authors are also thankful to University Grant Commission, New Delhi, India for providing Dr DS Kothari-Postdoctoral fellowship.

CONTRIBUTORS

Dr Pramod Kumar received his PhD from Defence Research & Development Establishment (DRDE), Gwalior, in 2010. He was a UGC-DS Kothari postdoctoral fellow at Jawaharlal Nehru University, New Delhi. Presently, he is doing post Doctoral Fellow at National Centre for Disease Control, New Delhi. His research focuses on mechanism of drug resistance in *Vibrio cholerae*.

Mr Jayprakash Yadav is pursuing his PhD from NIIT, Rourkela. He worked on antimicrobial properties of herbs.

Dr Meenu Jain obtained her PhD from DRDE, Gwalior. Now she is working as a DST- young scientist at Jiwaji University, Gwalior. She has worked on molecular characterisation of *V. cholerae* isolates.

Dr Preeti Yadav obtained her PhD from DRDE, Gwalior. Currently doing her Post-doctoral studies from Gandhi Post Graduate Institute of Medical Sciences, Lucknow. Her area of interest involved exploration of bioactive potential of Garlic and other herbs.

Dr A.K. Goel obtained his MSc and PhD from CCS Haryana Agricultural University, Hisar. Currently working as Scientist 'F' at DRDE, Gwalior. He was conferred several awards including the AMI Young Scientist Award-1999, DRDO Laboratory Scientist of the Year' award-2004, DRDO Young Scientist Award-2005, DRDO Technology Group Award-2006 & 2015, DBT Overseas Associateship-2008 and DRDO Technology Day Oration Award-2013. He is presently engaged in development of molecular and immunological systems for bio-threat agents.

Prof. P.K. Yadava received his PhD from Banaras Hindu University, Varanasi. Presently working as a Professor in JNU, New Delhi. His area of research is applied molecular biology.